The Changes Of VEGF And SDF-1 Levels In The Serum Of Patients With Moyamoya Disease

Objective:This study examined the expression of vascular endothelial growth factor(VEGF)and stromal cell-derived factor-1(SDF-l)in serum of patients with moyamoya disease to explore the role of VEGF and SDF-1 in moyamoya disease.Methods:Patients who were diagnosed as moyamoya disease by Digital Subtraction Angiography(DSA)and informed consent at the Second Affiliated Hospital of Nanchang University were collected.According to the clinical manifestations,they were divided into cerebral infarction group and cerebral hemorrhage group.In addition,the normal population of the physical examination center of the Second Affiliated Hospital of Nanchang University was used as the control group.In the morning,5 ml of peripheral venous blood was collected from patients with fasting of moyamoya disease and healthy controls using EDTA anticoagulant tubes.After 10-20 minutes of standing at room temperature,centrifugation was conducted at a speed of3000 rpm for 15 minutes.The supernatant was collected and labeled into 2 parts and frozen in a-80° refrigerator.Finally,the expression of VEGF and SDF-1 in serum was analyzed by immuno-enzyme-linked immunosorbent assay(ELISA).SPSS 22.0statistical processing data.Results:1.A total of 20 patients with moyamoya disease were collected in our study,there were 7 males(35%),13 fe males(65%),the proportion of men and women was1:l.86;the age range was 21-56 years,and the average age of them was 41.2 ± 10.5.10 cases of ischemic and 10 cases of bleeding were included in the study.There was no significant difference between the age of the control group and patients with moyamoya disease(38.8±8.95 vs.41.2±10.5 years;P>0.05).2.The serum levels of VEGF in patients with moyamoya disease weresignificantly different from those in the normal control group(391.4±148.3 ng/L vs91.7±51.1 ng/L;P<0.01).Further analysis of the subtypes revealed that ischemic group had statistically significant differences from the control group(406.9±131.0 VS91.7±51.1 ng/L,P<0.01);The bleeding group had statistically significant difference from the control group(386.1 ± 135.5 VS 91.7 ± 51.1ng/L,P<0.01);The ischemic group had no statistically significant difference from the bleeding group(406.9±131.0VS 386.1 ± 135.5ng/L;P=0.731).3.The serum level of SDF-1 in patients with moyamoya disease was significantly different from the normal control group(1633.8 ±160.9 VS 1509.5±137.4 pg/L,P<0.05).Further analysis of the subtypes revealed that ischemic group had statistically significant differences from the control group(1684.1±153.1 VS1509.5±137.4 pg/L,P<0.01);The ischemic group had no statistically significant difference from the bleeding group(1684.1±153.1 VS 1583.9 ± 169.6pg/L;P=0.168);The bleeding group had no statistically significant difference from the control group(1583.9 ± 169.6 VS 1509.5 ±137.4 pg/L,P<0.01).4.The Pearson correlation analysis of SDF-1 content and VEGF content in serum of patients with moyamoya disease showed that there was a positive correlation between them(r=0.602,P<0.05).Conclusion:1.VEGF and SDF-1 may be involved in the formation of new blood vessels in moyamoya disease.2.VEGF and SDF-1 may have synergistic effects in the formation of neovascularization in moyamoya disease.